Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CBX-12 in Pediatric Patients With Relapsed or Refractory Solid Tumors
NCT07830667Phase 2Not yet recruiting
- Sponsor
- Children's Oncology Group
- Start
- May 2027
- Primary completion
- Jun 2033
01
Overview
Phase 2, open-label, single-arm trial of alphalex exatecan in rhabdomyosarcoma (RMS) and Ewing sarcoma, sponsored by Children's Oncology Group. Primary endpoints: Maximum tolerated dose, Recommended phase 2 dose and 3 more. Planned start May 2027; status: not yet recruiting.
02
Drugs
alphalex exatecan
03
Conditions
rhabdomyosarcoma (RMS)Ewing sarcoma
Beyond the preview
Go deeper on NCT07830667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07830667.